The RheumNow Week in Review – 25 August 2017 Save

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes new data on IL-1 and pregnancy, contraceptives and the risk of RA, Calprotectin the biomarker, T2T failing, and the loss of a giant in rheumatology.

1. Data on IL-1 inhibitors and pregnancy: 11 paternal & 31 maternal (23 Anakinra, 8 Cannakinumab) exposures, mosly live births and only  1 renal agenesis/ectopic neurohypophysis.  https://buff.ly/2wstyyA
2. 435 Nordic JIA pts, Uveitis found in 20.5%; 90% asympt. Predictors of uveitis were ANA+, AHA+, JIA onset <7yrs in girls, not boys  https://buff.ly/2ise342
3. Study of 215 RA patients Rx with DMARDs & T2T strategy. Serum Calprotectin shown to be strong biomarker; significantly correlated with ESR, CDAI, US Power doppler, Xray progression https://t.co/82YvTFtcAV
4. 4666 elderly Canadian RA patients, only 59% were deemed to be adherent to biologic therapy, Nonadherent used more steroids https://t.co/kmEmgmmc4p
5. 55% Americans take prescription medicine; now more than ever. https://t.co/3ytMXHHhVP
6. Swedish EIRA study: Oral contraceptive use decreases risk of ACPA+ RA. breast feeding has no effect. Ever/past oral contraceptive users have a decreased risk of ACPA-positive RA (OR=0.84) https://t.co/7p9wpfHBJY
7. Ironwood announces FDA approval of its combo drug lesinurad/allopurinol (Duzallo) in a 200/300 tablet. Could this be useful? https://t.co/lcUZTieKqg
8. 30 yoF with non itchy, nonpainful palpable purpura lesions on legs & abdomen on/off for last 8 mos. Patient has Hx of HBV Rx with Tenovir. What would you do next?
9. Leukocytoclastic vasculitis is most commonly caused by antibiotic use (Cipro, Cefazolin ) https://t.co/I893XN737C
10. Non-Tuberculous Mycobacterial Infections - Diagnosis and Management for the Rheumatologist
11. IV Golimumab Shines in Psoriatic Arthritis  
12. Treat-to-Target a Bust with Rheumatologists   
13. It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk 
14. Dr. H. Ralph Schumacher (1933-2017) 
15. Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA